PMC:7195088 / 60242-61274 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T95","span":{"begin":398,"end":406},"obj":"Body_part"},{"id":"T96","span":{"begin":415,"end":419},"obj":"Body_part"}],"attributes":[{"id":"A95","pred":"fma_id","subj":"T95","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T49","span":{"begin":415,"end":419},"obj":"Body_part"}],"attributes":[{"id":"A49","pred":"uberon_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T101","span":{"begin":476,"end":485},"obj":"Phenotype"},{"id":"T102","span":{"begin":701,"end":720},"obj":"Phenotype"}],"attributes":[{"id":"A101","pred":"hp_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A102","pred":"hp_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T344","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"T345","span":{"begin":164,"end":173},"obj":"Disease"},{"id":"T346","span":{"begin":330,"end":338},"obj":"Disease"},{"id":"T347","span":{"begin":381,"end":393},"obj":"Disease"},{"id":"T348","span":{"begin":420,"end":426},"obj":"Disease"},{"id":"T349","span":{"begin":476,"end":485},"obj":"Disease"},{"id":"T350","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"T351","span":{"begin":643,"end":651},"obj":"Disease"},{"id":"T352","span":{"begin":666,"end":670},"obj":"Disease"},{"id":"T353","span":{"begin":696,"end":700},"obj":"Disease"},{"id":"T354","span":{"begin":701,"end":720},"obj":"Disease"},{"id":"T355","span":{"begin":1014,"end":1022},"obj":"Disease"}],"attributes":[{"id":"A344","pred":"mondo_id","subj":"T344","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A345","pred":"mondo_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A346","pred":"mondo_id","subj":"T346","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A347","pred":"mondo_id","subj":"T347","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A348","pred":"mondo_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A349","pred":"mondo_id","subj":"T349","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A350","pred":"mondo_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A351","pred":"mondo_id","subj":"T351","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A352","pred":"mondo_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A353","pred":"mondo_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A354","pred":"mondo_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A355","pred":"mondo_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T332","span":{"begin":195,"end":207},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T333","span":{"begin":415,"end":419},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T334","span":{"begin":415,"end":419},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7997","span":{"begin":106,"end":120},"obj":"Chemical"},{"id":"T21891","span":{"begin":289,"end":304},"obj":"Chemical"},{"id":"T62412","span":{"begin":609,"end":624},"obj":"Chemical"},{"id":"T11802","span":{"begin":897,"end":904},"obj":"Chemical"},{"id":"T65","span":{"begin":969,"end":976},"obj":"Chemical"}],"attributes":[{"id":"A45164","pred":"chebi_id","subj":"T7997","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A84381","pred":"chebi_id","subj":"T21891","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A28842","pred":"chebi_id","subj":"T62412","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A8182","pred":"chebi_id","subj":"T11802","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A19409","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T29","span":{"begin":381,"end":393},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T440","span":{"begin":0,"end":20},"obj":"Sentence"},{"id":"T441","span":{"begin":21,"end":174},"obj":"Sentence"},{"id":"T442","span":{"begin":175,"end":341},"obj":"Sentence"},{"id":"T443","span":{"begin":342,"end":803},"obj":"Sentence"},{"id":"T444","span":{"begin":804,"end":1032},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

2_test

{"project":"2_test","denotations":[{"id":"32360444-31986264-22369807","span":{"begin":535,"end":537},"obj":"31986264"},{"id":"32360444-22088618-22369808","span":{"begin":538,"end":540},"obj":"22088618"},{"id":"32360444-32192578-22369809","span":{"begin":541,"end":543},"obj":"32192578"}],"text":"Question 5 statement\nSo far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid administration in patients with SARS-CoV-2 infection. As the World Health Organization underlines, there is an important need for efficacy data from RCT for supporting corticosteroids therapy in patients with SARS-CoV-2. However, considering that overwhelming inflammation and cytokine-related lung injury might be responsible for the rapidly progressive pneumonia and clinical deterioration in COVID-19 patients [44,58,67], we suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19 patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections (independent of ICU admission). However, in the absence of convincing evidence, the following cannot currently be supported: steroid administration stratified according to inflammatory markers and steroid administration in non–critically ill COVID-19 patients."}

PMC:7195088 / 60242-61274 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7195088 / 60242-61274 JSON TXT